← Leaderboards
Kristina Abel
Univ Of North Carolina Chapel Hill
$26,837,151
Attributed
$30,091,988
Total exposure
40
Grants
33
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,702,432 · 43
By mechanism
P01$28,642,116 · 18
R01$14,313,376 · 4
P51$2,256,209 · 15
R21$2,090,730 · 5
R56$400,001 · 1
Top collaborators
- Sallie R. Permar16 shared
- Glenn J Fennelly7 shared
- Michelle H Larsen7 shared
Others in their field
Top investigators on “Infant”
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Carol Nesel · Westat$188,148,170
- Barbara Driver · Westat, Inc.$184,782,231
- Abhik Das · Research Triangle Institute$178,442,979
- Elizabeth A Thom · George Washington University$170,837,172
- J Brooks Jackson · Social And Scientific Systems, Inc.$150,941,831
Research focus
InfantInfectionMacaca MulattaVaccinesImmune ResponseImmuneAdultResponseAntibodiesVaccinationImmune SystemHiv VaccineChildhoodB-LymphocytesAdjuvantImmunizationImmunityTransmission ProcessMacacaHiv-1AntigensResourcesNeutralizing AntibodyPrevent
Grant awards (94)
Translating germline-targeting HIV Env SOSIP immunization of infants: targeting bnAbs in early life$4,630,686
P01 · FY2025 · AI
Determinants of HIV broadly-neutralizing antibody precursor induction in infants$1,516,969
P01 · FY2025 · AI · contact PI
Immune Analytics Core (IAC)$911,671
P01 · FY2025 · AI · contact PI
Core A: Administrative Core$252,829
P01 · FY2025 · AI · contact PI
Core C: B Cell Core$252,829
P01 · FY2025 · AI · contact PI
Core B: Non-human Primate Core$252,829
P01 · FY2025 · AI · contact PI
Project 1: The impact of innate immune responses on the development of broadly neutralizing antibodies by vaccination$252,827
P01 · FY2025 · AI · contact PI
Project 2: Microbial determinants of HIV broadly-neutralizing antibody precursor induction in infants$252,827
P01 · FY2025 · AI · contact PI
Determinants of HIV broadly-neutralizing antibody precursor induction in infants$1,518,131
P01 · FY2024 · AI · contact PI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$1,370,057
P01 · FY2024 · AI
Project-002$668,200
P01 · FY2024 · AI
Core B: Non-human Primate Core$500,699
P01 · FY2024 · AI · contact PI
Core-001$435,818
P01 · FY2024 · AI
Admin-Core-001$266,039
P01 · FY2024 · AI
Project 1: The impact of innate immune responses on the development of broadly neutralizing antibodies by vaccination$258,043
P01 · FY2024 · AI · contact PI
Project 2: Microbial determinants of HIV broadly-neutralizing antibody precursor induction in infants$242,474
P01 · FY2024 · AI · contact PI
Core C: B Cell Core$240,080
P01 · FY2024 · AI · contact PI
Vaccine-induced SARS-CoV-2-specific T cell responses in patients with X-linked Agammaglobulinemia$195,770
R21 · FY2024 · AI · contact PI
Core A: Administrative Core$135,169
P01 · FY2024 · AI · contact PI
Determinants of HIV broadly-neutralizing antibody precursor induction in infants$1,584,559
P01 · FY2023 · AI · contact PI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$1,381,667
P01 · FY2023 · AI
Core-002$541,944
P01 · FY2023 · AI
Core B: Non-human Primate Core$458,273
P01 · FY2023 · AI · contact PI
Project 2: Microbial determinants of HIV broadly-neutralizing antibody precursor induction in infants$311,058
P01 · FY2023 · AI · contact PI
Core C: B Cell Core$267,837
P01 · FY2023 · AI · contact PI
Project 1: The impact of innate immune responses on the development of broadly neutralizing antibodies by vaccination$256,118
P01 · FY2023 · AI · contact PI
Vaccine-induced SARS-CoV-2-specific T cell responses in patients with X-linked Agammaglobulinemia$249,863
R21 · FY2023 · AI · contact PI
Core A: Administrative Core$149,607
P01 · FY2023 · AI · contact PI
Admin-Core-002$138,007
P01 · FY2023 · AI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$1,375,878
P01 · FY2022 · AI
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants$911,707
R01 · FY2022 · DE · contact PI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$1,397,532
P01 · FY2021 · AI
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants$920,833
R01 · FY2021 · DE · contact PI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$299,339
P01 · FY2021 · AI
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques$46,196
P01 · FY2021 · AI · contact PI
Early Life Vaccination to Prevent HIV acquisition during Adolescence$1,307,799
P01 · FY2020 · AI
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques$1,227,827
P01 · FY2020 · AI
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants$905,447
R01 · FY2020 · DE · contact PI
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques$203,402
P01 · FY2020 · AI · contact PI
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants$899,083
R01 · FY2019 · DE · contact PI
Development of a pediatric vaccine to protect against clade C HIV-1 infection$414,302
P01 · FY2019 · AI · contact PI
Subingual-parenteral Vaccination to Prevent Oral HIV Transmission in Infants$994,542
R01 · FY2018 · DE · contact PI
Development of a pediatric vaccine to protect against clade C HIV-1 infection$204,261
P01 · FY2018 · AI · contact PI
Development of a pediatric vaccine to protect against clade C HIV-1 infection$369,948
P01 · FY2017 · AI · contact PI
The Pros and Cons of Trained Immunity Induced by Vaccines for Tuberculosis Prevention$228,000
R21 · FY2017 · AI · contact PI
Optimizing Oral Pediatric HIV Vaccines to Prevent Breast Milk Transmission$908,245
R01 · FY2016 · DE · contact PI
Development of a pediatric vaccine to protect against clade C HIV-1 infection$533,938
P01 · FY2016 · AI · contact PI
The Interplay of Oral Vaccines, Oral Immunity and the Oral Microbiome in Infants$400,001
R56 · FY2016 · DE · contact PI
The Pros and Cons of Trained Immunity Induced by Vaccines for Tuberculosis Prevention$190,000
R21 · FY2016 · AI · contact PI
Development of a pediatric vaccine to protect against clade C HIV-1 infection$158,227
P01 · FY2016 · AI · contact PI
Optimizing Oral Pediatric HIV Vaccines to Prevent Breast Milk Transmission$917,623
R01 · FY2015 · DE · contact PI
Molecular Mechanisms Associated with Immune Maturation in Infants$554,931
R01 · FY2015 · AI · contact PI
Development of a pediatric vaccine to protect against clade C HIV-1 infection$370,234
P01 · FY2015 · AI · contact PI
Optimizing Oral Pediatric HIV Vaccines to Prevent Breast Milk Transmission$955,475
R01 · FY2014 · DE · contact PI
A Novel Oral Combination Pediatric HIV and TB Vaccine$501,915
R01 · FY2014 · DE · contact PI
Molecular Mechanisms Associated with Immune Maturation in Infants$408,517
R01 · FY2014 · AI · contact PI
Optimizing Oral Pediatric HIV Vaccines to Prevent Breast Milk Transmission$703,703
R01 · FY2013 · DE · contact PI
Molecular Mechanisms Associated with Immune Maturation in Infants$408,900
R01 · FY2013 · AI · contact PI
Optimizing Oral Pediatric HIV Vaccines to Prevent Breast Milk Transmission$266,693
R01 · FY2013 · DE · contact PI
Optimizing Oral Pediatric HIV Vaccines to Prevent Breast Milk Transmission$769,068
R01 · FY2012 · DE · contact PI
A Novel Oral Combination Pediatric HIV and TB Vaccine$502,986
R01 · FY2012 · DE · contact PI
Molecular Mechanisms Associated with Immune Maturation in Infants$443,860
R01 · FY2012 · AI · contact PI
A Novel Oral Combination Pediatric HIV and TB Vaccine$518,663
R01 · FY2011 · DE · contact PI
DEVELOPMENT OF A NOVEL PEDIATRIC COMBINATION VACCINE AGAINST HIV & TB INFECTION$191,444
P51 · FY2011 · RR · contact PI
DEVELOPMENT OF A SIV-MALARIA COINFECTION MODEL IN RHESUS MACAQUES$191,444
P51 · FY2011 · RR · contact PI
REPLICATING VIRAL VECTOR AS NEONATAL VACCINE TO PREVENT ORAL SIV TRANSMISSION$191,444
P51 · FY2011 · RR · contact PI
THE DEVELOPMENT OF AN INFANT RHESUS MACAQUE MODEL OF RHESUS CMV INFECTION$100,951
P51 · FY2011 · RR · contact PI
A Novel Oral Combination Pediatric HIV and TB Vaccine$545,865
R01 · FY2010 · DE · contact PI
THE DEVELOPMENT OF AN INFANT RHESUS MACAQUE MODEL OF RHESUS CMV INFECTION$152,094
P51 · FY2010 · RR · contact PI
DEVELOPMENT OF A NOVEL PEDIATRIC COMBINATION VACCINE AGAINST HIV & TB INFECTION$152,094
P51 · FY2010 · RR · contact PI
DEVELOPMENT OF A SIV-MALARIA COINFECTION MODEL IN RHESUS MACAQUES$152,094
P51 · FY2010 · RR · contact PI
A Novel Oral Combination Pediatric HIV and TB Vaccine$557,895
R01 · FY2009 · DE · contact PI
DEVELOPMENT OF A NOVEL PEDIATRIC COMBINATION VACCINE AGAINST HIV & TB INFECTION$146,581
P51 · FY2009 · RR · contact PI
DEVELOPMENT OF A SIV-MALARIA COINFECTION MODEL IN RHESUS MACAQUES$146,580
P51 · FY2009 · RR · contact PI
ROLE OF TYPE I INTERFERONS IN SIV PATHOGENESIS$146,580
P51 · FY2009 · RR · contact PI
THE DEVELOPMENT OF AN INFANT RHESUS MACAQUE MODEL OF RHESUS CMV INFECTION$142,267
P51 · FY2009 · RR · contact PI
A Rhesus Macaque Model of SIV-Malaria Co-Infection$109,750
R21 · FY2009 · AI · contact PI
A Nonhuman Primate Model of Infant CMV Infection$95,470
R21 · FY2009 · HD · contact PI
A Nonhuman Primate Model of Infant CMV Infection$84,000
R21 · FY2009 · HD · contact PI
A Rhesus Macaque Model of SIV-Malaria Co-Infection$70,502
R21 · FY2009 · AI · contact PI
A Novel Oral Combination Pediatric HIV and TB Vaccine$29,585
R01 · FY2009 · DE · contact PI
A Novel Oral Combination Pediatric HIV and TB Vaccine$687,840
R01 · FY2008 · DE · contact PI
Innate Immunity in Live-Attenuated AIDS Vaccines$453,115
P01 · FY2008 · AI · contact PI
A Nonhuman Primate Model of Infant CMV Infection$228,000
R21 · FY2008 · HD · contact PI
A Rhesus Macaque Model of SIV-Malaria Co-Infection$226,500
R21 · FY2008 · AI · contact PI
DEVELOPMENT OF A SIV-MALARIA COINFECTION MODEL IN RHESUS MACAQUES$168,995
P51 · FY2008 · RR · contact PI
ROLE OF TYPE I INTERFERONS IN SIV PATHOGENESIS$168,995
P51 · FY2008 · RR · contact PI
Innate Immunity in Live-Attenuated AIDS Vaccines$459,432
P01 · FY2007 · AI · contact PI
ROLE OF TYPE I INTERFERONS IN SIV PATHOGENESIS$181,571
P51 · FY2007 · RR · contact PI
Innate Immunity in Live-Attenuated AIDS Vaccines$405,641
P01 · FY2006 · AI · contact PI
Innate Immunity in Live-Attenuated AIDS Vaccines$367,798
P01 · FY2005 · AI
Role of type I interferons in mucosal anti-SIV immunity$189,375
R21 · FY2005 · DE
Role of type I interferons in mucosal anti-SIV immunity$223,500
R21 · FY2004 · DE
IL-2SA THERAPY IN SIV INFECTTION$23,075
P51 · FY2004 · RR